Interview with Klaus Heumann, Founder and CEO, Biomax Informatics
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Address: Robert-Koch-Str. 2
D-82152 Planegg
Germany
Tel: +49 (0) 89 895574-0
Web: http://www.biomax.com/home/home.php
Biomax was founded in 1997 with the mission to develop software solutions based on the actual needs of life science organizations.
In pursuit of this goal, Biomax developed a systematic client consultation process that includes evaluation, feedback and optimization. As a result, Biomax has developed software solutions which address both highly specific and general research needs along the discovery-process pipeline. These software tools and content offer a robust foundation for expanding and building new bioinformatics solutions.
Today, life science organizations need access to relevant knowledge at the right time and in the right context to cut costs and enable efficient prioritization of research and production tasks based on well-defined objectives. To meet this need, Biomax provides computational and knowledge solutions which infer and manage the knowledge indispensable for efficient decision making.
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
See our Cookie Privacy Policy Here
